A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

This study is currently recruiting participants.
Verified February 2013 by Genentech
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT01456325
First received: October 18, 2011
Last updated: February 26, 2013
Last verified: February 2013
  Purpose

This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in patients with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Patients will be randomized to receive either onartuzumab (MetMAb) or placebo in combination with Tarceva. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.


Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: onartuzumab [MetMAb]
Drug: erlotinib [Tarceva]
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease

Resource links provided by NLM:


Further study details as provided by Genentech:

Primary Outcome Measures:
  • Overall survival [ Time Frame: time from randomization to death due to any cause, up to approximately 40 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival, tumor assessments according to RECIST criteria [ Time Frame: time between date of randomization and the date of first documented disease progression or death, whichever occurs first, up to approximately 40 months ] [ Designated as safety issue: No ]
  • Overall response rate (complete response + partial response) [ Time Frame: up to approximately 40 months ] [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Time Frame: up to approximately 40 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 490
Study Start Date: July 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: onartuzumab [MetMAb]
Repeating intravenous dose
Other Name: PRO143966
Drug: erlotinib [Tarceva]
Repeating oral dose
Active Comparator: B Drug: erlotinib [Tarceva]
Repeating oral dose
Drug: Placebo
Repeating intravenous dose

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor
  • Met diagnostic-positive status tested by IHC
  • Results of EGFR-activating mutation testing
  • Radiographic evidence of disease
  • Prior treatment with at least one platinum-based line of treatment (for stage IIIb/IV) and no more than one additional line of chemotherapy treatment; the last dose of chemotherapy must have been administered >/= 21 days prior to Day 1
  • availability of tissue sample for diagnostic testing is required

Exclusion Criteria:

  • More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known EGFR-related toxicity resulting in dose modifications (EGFR inhibitors including but not limited to gefitinib, erlotinib and cetuximab)
  • Brain metastases or spinal cord compression not definitively treated with surgery and/or radiation, or previously treated central nervous system (CNS) metastases or spinal cord compression without evidence of stable disease for >/= 14 days
  • History of another malignancy in the previous 3 years, unless cured by surgery alone and continuously disease free for at least 3 years; patients with prior history of non-invasive cancers are eligible
  • Inadequate hematological, biochemical or organ function
  • Significant history of cardiac disease
  • Serious active infection at time of randomization or other serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment
  • Any inflammatory changes of the surface of the eye
  • Clinically significant gastro-intestinal disease, including uncontrolled inflammatory gastro-intestinal diseases
  • Pregnant or lactating women
  • Positive for HIV infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01456325

Contacts
Contact: Please reference Study ID Number: GO27761 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) genentechclinicaltrials@druginfo.com

  Hide Study Locations
Locations
United States, Arizona
Recruiting
Chandler, Arizona, United States, 85224
United States, California
Recruiting
Hayward, California, United States, 94545
Not yet recruiting
Los Angeles, California, United States, 90095
Recruiting
Modesto, California, United States, 95355
Recruiting
Oakland, California, United States, 94611
Recruiting
Orange, California, United States, 92868
Recruiting
Roseville, California, United States, 95661
Recruiting
Sacramento, California, United States, 95825
Recruiting
Sacramento, California, United States, 95817
Recruiting
San Diego, California, United States, 92108
Recruiting
San Francisco, California, United States, 94115
Recruiting
San Jose, California, United States, 95119
Recruiting
Santa Clara, California, United States, 95051
Recruiting
South San Francisco, California, United States, 94080
Recruiting
Vallejo, California, United States, 94589
Recruiting
Walnut Creek, California, United States, 94596
United States, Florida
Recruiting
Boca Raton, Florida, United States, 33486
Recruiting
Clearwater, Florida, United States, 33761
Recruiting
Fort Myers, Florida, United States, 33916
Recruiting
Jacksonville, Florida, United States, 32256
Recruiting
Jacksonville, Florida, United States, 32207
United States, Illinois
Recruiting
Chicago, Illinois, United States, 60637
Recruiting
Urbana, Illinois, United States, 61801
United States, Iowa
Recruiting
Bettendorf, Iowa, United States, 52722
Recruiting
Sioux City, Iowa, United States, 51101
United States, Kentucky
Recruiting
Louisville, Kentucky, United States, 40207
United States, Maryland
Recruiting
Annapolis, Maryland, United States, 21401
Not yet recruiting
Baltimore, Maryland, United States, 21201
Recruiting
Baltimore, Maryland, United States, 21237
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States, 02115
Recruiting
Boston, Massachusetts, United States, 02114
Not yet recruiting
Springfield, Massachusetts, United States, 01107
United States, Michigan
Recruiting
Ann Arbor, Michigan, United States, 48106
United States, Minnesota
Recruiting
Duluth, Minnesota, United States, 55805
United States, Missouri
Recruiting
St. Louis, Missouri, United States, 63110
United States, Nebraska
Recruiting
Omaha, Nebraska, United States, 68114
United States, Nevada
Recruiting
Reno, Nevada, United States, 89502
United States, New Mexico
Recruiting
Farmington, New Mexico, United States, 87401
United States, New York
Recruiting
Syracuse, New York, United States, 13210
United States, Ohio
Recruiting
Canton, Ohio, United States, 44718
Recruiting
Cleveland, Ohio, United States, 44106
Recruiting
Columbus, Ohio, United States, 43210
Recruiting
Columbus, Ohio, United States, 43219
United States, Pennsylvania
Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Recruiting
Pittsburgh, Pennsylvania, United States, 15232
United States, South Carolina
Recruiting
Charleston, South Carolina, United States, 29425
Recruiting
Columbia, South Carolina, United States, 29210
United States, Tennessee
Recruiting
Bristol, Tennessee, United States, 37620
Recruiting
Chattanooga, Tennessee, United States, 37404
Recruiting
Knoxville, Tennessee, United States, 37909
Recruiting
Nashville, Tennessee, United States, 37203
United States, Texas
Recruiting
Dallas, Texas, United States, 75390
Recruiting
Fort Worth, Texas, United States, 76104
Recruiting
Houston, Texas, United States, 77030
United States, Virginia
Recruiting
Roanoke, Virginia, United States, 24014
Argentina
Not yet recruiting
Córdoba, Argentina, 5000
Recruiting
La Plata, Argentina, B1900BAJ
Recruiting
Quilmes, Argentina, 1878
Recruiting
Santa Fe, Argentina, S3000FFU
Australia
Recruiting
Bedford Park, Australia, 5042
Recruiting
Camperdown, Australia, 2050
Recruiting
Chermside, Australia, 4032
Recruiting
Newcastle, Australia, 2298
Recruiting
Parkville, Australia, 3050
Belgium
Recruiting
Bruxelles, Belgium, 1200
Not yet recruiting
Gent, Belgium, 9000
Recruiting
Gilly, Belgium, 6060
Recruiting
Liège, Belgium, 4000
Recruiting
Namur, Belgium, 5000
Brazil
Not yet recruiting
Barretos, Brazil, 14784-400
Not yet recruiting
Botucatu, Brazil, 18618-000
Not yet recruiting
JAÚ, Brazil, 17210-120
Not yet recruiting
Lajeado, Brazil, 95900-000
Not yet recruiting
Novo Hamburgo, Brazil, 93510-250
Not yet recruiting
Porto Alegre, Brazil, 90610-000
Not yet recruiting
Salvador/ba, Brazil, 41820-021
Not yet recruiting
Sao Paulo, Brazil, 04038-001
Not yet recruiting
Sao Paulo, Brazil, 01246-000
Not yet recruiting
Sao Paulo, Brazil, 08270-070
Not yet recruiting
Sorocaba, Brazil, 18030-510
Canada, New Brunswick
Recruiting
Saint John, New Brunswick, Canada, E2L 4L2
Canada, Ontario
Recruiting
Sault Ste Marie, Ontario, Canada, P6A 2C4
Recruiting
Toronto, Ontario, Canada, M5G 2M9
Recruiting
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Not yet recruiting
Montreal, Quebec, Canada, J4B 5Z7
Recruiting
Montreal, Quebec, Canada, H3A 1A1
Chile
Recruiting
Santiago, Chile
Recruiting
Santiago, Chile, 664 0166
Recruiting
Temuco, Chile, 4810469
Croatia
Recruiting
Cakovec, Croatia, 40000
Recruiting
Dubrovnik, Croatia, 20000
Recruiting
Pula, Croatia, 52100
Recruiting
Zagreb, Croatia, 10000
France
Not yet recruiting
Besancon, France, 25030
Recruiting
Caen, France, 14076
Recruiting
Grenoble, France, 38043
Recruiting
Limoges, France, 87042
Recruiting
Marseille, France, 13915
Not yet recruiting
Montpellier, France, 34295
Recruiting
Paris, France, 75970
Recruiting
Poitiers, France, 86021
Recruiting
Saint Herblain, France, 44805
Recruiting
Suresnes, France, 92151
Recruiting
Vandoeuvre-les-nancy, France, 54510
Germany
Recruiting
Bad Berka, Germany, 99437
Recruiting
Berlin, Germany, 14165
Recruiting
Grosshansdorf, Germany, 22927
Recruiting
Hamburg, Germany, 21075
Recruiting
Heidelberg, Germany, 69126
Recruiting
Karlsruhe, Germany, 76137
Recruiting
Mainz, Germany, 55131
Recruiting
München, Germany, 80336
Recruiting
Oldenburg, Germany, 26121
Recruiting
Regensburg, Germany, 93053
Recruiting
ULM, Germany, 89081
Recruiting
Villingen-schwenningen, Germany, 78050
Hong Kong
Not yet recruiting
Hong Kong, Hong Kong
Recruiting
Hong Kong, Hong Kong
Recruiting
Pokfulam, Hong Kong
Hungary
Recruiting
Edeleny, Hungary, 3780
Recruiting
Miskolc, Hungary, 3529
Recruiting
Szombathely, Hungary, 9700
India
Not yet recruiting
Pune, India, 411004
Ireland
Recruiting
Cork, Ireland
Recruiting
Dublin, Ireland, 8
Israel
Recruiting
Beer Sheva, Israel, 84101
Recruiting
Haifa, Israel, 31096
Recruiting
Jerusalem, Israel, 91031
Recruiting
Jerusalem, Israel, 91120
Recruiting
Kfar Saba, Israel, 44281
Recruiting
Petach Tikva, Israel, 49100
Recruiting
Ramat-gan, Israel, 52621
Recruiting
Rehovot, Israel, 76100
Italy
Recruiting
Ancona, Italy, 60121
Recruiting
Aviano, Italy, 33081
Recruiting
Genova, Italy, 16132
Recruiting
Lido Di Camaiore, Italy, 55043
Recruiting
Milan, Italy, 20141
Recruiting
Monza, Italy, 20052
Recruiting
Orbassano, Italy, 10043
Recruiting
Perugia, Italy, 06123
Completed
Rozzano, Italy, 20089
Japan
Recruiting
Aichi, Japan, 464-8681
Recruiting
Chuo-ku, Japan, 103-0004
Recruiting
Fukuoka, Japan, 812-8582
Recruiting
Fukuoka, Japan, 811-1395
Recruiting
Hyogo, Japan, 673-8558
Recruiting
Itabashi-ku, Japan, 173-0806
Recruiting
Kanagawa, Japan, 236-0051
Recruiting
Kashiwa, Japan, 277-8577
Recruiting
Kyoto, Japan, 606-8507
Not yet recruiting
Matsuyama, Japan, 791-0280
Recruiting
Natori, Japan, 981-1293
Recruiting
Okayama, Japan, 700-8558
Recruiting
Okayama, Japan, 710-8602
Recruiting
Osaka, Japan, 537-8511
Not yet recruiting
Osaka, Japan, 589-8511
Recruiting
Osaka, Japan, 534-0021
Recruiting
Saitama, Japan, 362-0806
Recruiting
Sakai, Japan, 591-8555
Recruiting
Sendai-shi, Japan, 980-8574
Recruiting
Shizuoka, Japan, 411-8777
Recruiting
Tokyo, Japan, 104-0045
Recruiting
Tokyo, Japan, 135-8550
Recruiting
Tokyo, Japan, 113-8677
Recruiting
Tokyo, Japan, 160-0023
Recruiting
UBE, Japan, 775-0241
Korea, Republic of
Recruiting
Seoul, Korea, Republic of, 138-736
Recruiting
Seoul, Korea, Republic of, 137-807
Recruiting
Seoul, Korea, Republic of, 120-752
Recruiting
Suwon City, Korea, Republic of, 443-721
Netherlands
Recruiting
Amsterdam, Netherlands, 1081 HV
Recruiting
Groningen, Netherlands, 9713 GZ
Recruiting
Maastricht, Netherlands, 6229 HX
Peru
Recruiting
Lima, Peru, Lima 27
Recruiting
Lima, Peru, Lima 1
Recruiting
Lima, Peru, L27
Poland
Recruiting
Gdansk, Poland, 80-952
Recruiting
Krakow, Poland, 31-531
Recruiting
Lodz, Poland, 93-509
Recruiting
Olsztyn, Poland, 10-357
Recruiting
Poznan, Poland
Russian Federation
Recruiting
Ivanovo, Russian Federation, 153040
Recruiting
Krasnodar, Russian Federation, 350040
Recruiting
Omsk, Russian Federation, 644013
Recruiting
St Petersburg, Russian Federation, 197089
Recruiting
St. Petersburg, Russian Federation, 197022
Recruiting
St. Petersburg, Russian Federation, 189646
Terminated
Tyumen, Russian Federation, 625041
Serbia
Recruiting
Belgrade, Serbia, 11080
Recruiting
Belgrade, Serbia, 11000
Recruiting
Kragujevac, Serbia, 34000
South Africa
Recruiting
Bloemfontein, South Africa, 9301
Recruiting
Johannesburg, South Africa, 2193
Recruiting
Johannesburg, South Africa, 2199
Spain
Recruiting
Barcelona, Spain, 08035
Recruiting
Barcelona, Spain, 08041
Recruiting
Barcelona, Spain, 08036
Recruiting
Barcelona, Spain, 08916
Recruiting
Madrid, Spain, 28007
Recruiting
Madrid, Spain, 28050
Recruiting
Madrid, Spain, 28034
Recruiting
Madrid, Spain, 28222
Recruiting
Sabadell, Barcelona, Spain, 08208
Recruiting
Sevilla, Spain, 41013
Recruiting
Valencia, Spain, 41014
Taiwan
Recruiting
Changhua, Taiwan, 500
Not yet recruiting
Kaohsiung, Taiwan, 813
Recruiting
Taipei, Taiwan, 100
Not yet recruiting
Taoyuan, Taiwan, 333
Ukraine
Recruiting
Cherkassy, Ukraine, 18009
Recruiting
Chernivtsi, Ukraine, 58013
Recruiting
Dnipropetrovsk, Ukraine, 49102
Recruiting
Sumy, Ukraine, 40005
Recruiting
Zaporizhzhya, Ukraine, 69040
United Kingdom
Recruiting
Belfast, United Kingdom, BT9 7AB
Recruiting
Grimsby, United Kingdom, DN33 2BA
Recruiting
Leicester, United Kingdom, LE1 5WW
Recruiting
London, United Kingdom, SE1 9RT
Recruiting
London, United Kingdom, SW10 9NH
Recruiting
Manchester, United Kingdom, M2O 4BX
Sponsors and Collaborators
Genentech
Hoffmann-La Roche
Investigators
Study Director: Holger Thurm, M.D. Genentech
  More Information

No publications provided

Responsible Party: Genentech
ClinicalTrials.gov Identifier: NCT01456325     History of Changes
Other Study ID Numbers: OAM4971g, GO27761, 2011-002224-40
Study First Received: October 18, 2011
Last Updated: February 26, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasm Metastasis
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neoplastic Processes
Pathologic Processes
Erlotinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013